Companies
Capricor Therapeutics
its lead asset Deramiocel (formerly CAP-1002), an allogeneic cardiosphere-derived cell therapy whose benefit in Duchenne muscular dystrophy is believed to work partly through paracrine exosome secretion, has a Biologics License Application now scheduled for FDA Advisory Committee review on July 29, 2026,…
- Country
- United States
- Ticker
- CAPR
cell-therapy
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $278.6 million in cash, cash equivalents and marketable securities as of March 31, 2026 | biospace.com · capricor.com |
| Capacity | Scaling to approximately 2,000–2,500 patients per year or 10,000 doses annually at full capacity upon validation | biospace.com · capricor.com |
| Certification | GMP compliant manufacturing facility in San Diego successfully completed an FDA Pre-License Inspection | biospace.com · capricor.com · sec.gov |
| Regulatory approval | Deramiocel has Orphan Drug, RMAT, ATMP, and Rare Pediatric Disease designations; BLA under FDA review with PDUFA date of August 22, 2026 | biospace.com · capricor.com · sec.gov |
| Production site | GMP manufacturing facility in San Diego, California | biospace.com · capricor.com |
| Headcount | Approximately 247-299 employees as of mid-2026 medium confidence | altindex.com · finance.yahoo.com |
| Revenue | $0 revenue for the first quarter of 2026 and for the full year 2025 | biospace.com · capricor.com |
Independent sources: altindex.com · biospace.com · finance.yahoo.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Exosome therapy & extracellular vesicles | regenerative-personalized | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.